A study published in Oncotarget showed that combining TAS102 and regorafenib inhibits ERK1/2 and STAT3 signaling in gastrointestinal cancers. Both drugs are approved for metastatic colorectal cancer treatment. The study found that the combination delayed disease progression regardless of KRAS or BRAF mutational status. In preclinical studies, the combination had synergistic activity against colorectal and gastric cancer but not liver cancer. Regorafenib inhibited TAS102-induced angiogenesis and microvessel density in tumors. The combination is a potential treatment option for advanced gastrointestinal cancers and warrants further study. The findings were published by Impact Journals LLC in 2024.
Source link
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: Study
